top of page
REVEAL-BTC
A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER
CLINICAL TRIAL DETAILS
REVEAL-BTC is a retrospective, observational, case-only study designed to evaluate the expression of five potential therapeutic biomarkers (CLDN18.2, HER2, TROP2, PD-L1 and B7-H4) in archival tumor samples from patients diagnosed with biliary tract cancer (BTC), including gallbladder carcinoma (GBC) and cholangiocarcinoma (CCA). A total of 244 participants are expected to be included. Tumor samples will be analyzed using immunohistochemistry (IHC), and biomarker expression will be correlated with clinical outcomes to improve patient stratification and support future biomarker-driven treatment strategies in BTC.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
Biliary Tract Cancer (BTC)
0
244
Observational
Spain
Not yet recruiting
TRIAL OVERVIEW
PRESS RELEASE
-
SCIENTIFIC IMPACT
-
BLOG ARTICLES RELATED
-
TRIAL SITES
-
Dr. Cortes and Dr. Llombart PHERain interview
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
TRIAL RESUME
bottom of page